180465-55-8

Usage

Uses

Used in Pharmaceutical Industry:
SPIRO[INDENE-1,4'-PIPERIDIN]-3(2H)-ONE is used as a pharmaceutical candidate for its potential therapeutic applications. Its unique structure and pharmacological properties make it a promising target for drug discovery and development, with the aim of identifying new treatments for various diseases and conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, SPIRO[INDENE-1,4'-PIPERIDIN]-3(2H)-ONE serves as an interesting target for further research. Its unique structure and potential biological activities provide a foundation for exploring its interactions with biological targets and understanding its mechanism of action, which could lead to the development of novel therapeutic agents.
Used in Drug Discovery and Development:
SPIRO[INDENE-1,4'-PIPERIDIN]-3(2H)-ONE is utilized in drug discovery and development processes to identify its potential as a lead compound. Its unique structure and pharmacological properties make it a valuable asset in the search for new drugs with improved efficacy, safety, and selectivity.
Used in Chemical Synthesis:
In the realm of chemical synthesis, SPIRO[INDENE-1,4'-PIPERIDIN]-3(2H)-ONE can be employed as a building block or intermediate in the synthesis of more complex molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Overall, SPIRO[INDENE-1,4'-PIPERIDIN]-3(2H)-ONE is a versatile and promising compound with a wide range of potential applications across different industries, particularly in the fields of pharmaceuticals and medicinal chemistry. Its unique structure and potential biological activities make it an exciting target for further research and development.

Upstream product

• 6163-66-2 2,2'-oxybis(2-methyl-propane) 
• 100-39-0 benzyl bromide 
• 137419-24-0 1'-(tert-butyloxycarbonyl)spiro<1H-indene-1,4'-piperidine> 
• 159634-59-0 2,3-dihydro-3-oxo-spiro[1H-indene-1,4'-piperidine]-1'-carboxylic acid 1,1-dimethylethyl ester 

Downstream Products

• 209280-12-6 1'-(3-((S)-(3-chlorophenyl))-4-(N-(phenylsulfonyl)(methyl-amino))-butyl)-spiro(indan-1-one-3,4'-piperidine) 
• 855849-88-6 1'-[trans-3-(4-chlorophenyl)allyl]spiro[indan-1-one-3,4'-piperidine] 
• 917898-66-9 1-neopentyl-1'-(2-nitrophenyl)-2',3'-dihydro-1'H-spiro[piperidine-4,4'-quinoline] 
• 159634-63-6 Spiro(2-oxo-1,2,3,4-tetrahydroquinoline-4,4'-piperidine) 
• 185525-96-6 C₃₂H₄₁N₃O₆ 
• 185526-08-3 C₃₃H₄₃N₃O₅ 
• 185525-95-5 C₂₃H₂₆N₂O₃ 
• 878167-49-8 benzyl 3-oxo-2,3-dihydrospiro[indene-1,4'-piperidine]-1'-carboxylate 
• 185525-94-4 C₂₈H₃₄N₂O₅ 

Relevant academic research and scientific papers

Conformationally constrained ortho- Anilino diaryl ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl) -3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist

Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y1 antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y12 antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 3l will also be presented. Compound 3l was our first P2Y1 antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of muscarinic receptors

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions

The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.

AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE

A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R 5, are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X7 are also disclosed.

INSECTICIDAL SPIROINDANE DERIVATIVES

An insecticidal compound of formula I wherein X is O or NR11 where R11is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; Y is a single bond, C=O, C=S or S(O)m where

The synthesis and activity of spiroindane growth hormone secretagogues

The synthesis and activities of a series of spiroindane growth hormone secretagogues is reported. Modification of the benzylic position of the spiroindane has resulted in a dramatic increase in potency resulting in subnanomolar peptidomimetic growth hormone secretagogues. In vivo data demonstrating the good oral activity of these analogs is reported.